Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C31H24F2N4O3 |
| Molecular Weight | 538.5441 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=C(OC2=C1C(F)=C(C=C2)C3=CC(=CC=C3C)C(=O)NC4(CC4)C5=NC=CC=N5)C6=CC=C(F)C=C6
InChI
InChIKey=LZAUGCMVNLZVJV-UHFFFAOYSA-N
InChI=1S/C31H24F2N4O3/c1-17-4-5-19(28(38)37-31(12-13-31)30-35-14-3-15-36-30)16-22(17)21-10-11-23-24(26(21)33)25(29(39)34-2)27(40-23)18-6-8-20(32)9-7-18/h3-11,14-16H,12-13H2,1-2H3,(H,34,39)(H,37,38)
| Molecular Formula | C31H24F2N4O3 |
| Molecular Weight | 538.5441 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Bristol-Myers Squibb developed BMS-929075 as a selective, orally bioavailable hepatitis C virus (HCV) NS5B polymerase inhibitor for the treatment of chronic HCV infection. BMS-929075 was involved in phase I clinical trials for hepatitis C virus (HCV) infected patients; however, the company withdrew a study prior to enrolment.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:39:44 GMT 2023
by
admin
on
Sat Dec 16 11:39:44 GMT 2023
|
| Record UNII |
8S38482CST
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
59275404
Created by
admin on Sat Dec 16 11:39:44 GMT 2023 , Edited by admin on Sat Dec 16 11:39:44 GMT 2023
|
PRIMARY | |||
|
DB14950
Created by
admin on Sat Dec 16 11:39:44 GMT 2023 , Edited by admin on Sat Dec 16 11:39:44 GMT 2023
|
PRIMARY | |||
|
8S38482CST
Created by
admin on Sat Dec 16 11:39:44 GMT 2023 , Edited by admin on Sat Dec 16 11:39:44 GMT 2023
|
PRIMARY | |||
|
1217338-97-0
Created by
admin on Sat Dec 16 11:39:44 GMT 2023 , Edited by admin on Sat Dec 16 11:39:44 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Bristol-Myers Squibb; Class: Indoles; Mechanism of Action: Hepatitis C virus NS 5 protein inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: No development reported for Hepatitis C; Most Recent Events: 20 Jun 2016 No development reported - Preclinical for Hepatitis C in USA (PO), 20 Jun 2013 Bristol-Myers Squibb withdraws a phase I trial in Hepatitis C (treatment-naive) prior to enrolment (NCT01525212), 31 Jan 2012 Preclinical trials in Hepatitis C in USA (unspecified route)
|
||
|
ACTIVE MOIETY |
Official Title: Double-Blinded, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of BMS-929075 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1
Purpose: The purpose of this study is to determine the change from baseline in HCV Ribonucleic acid (RNA) on Day 4 following three days of dosing with BMS-929075 in chronically genotype subtype 1a and 1b HCV infected subjects.
|
